Introduction

With more an estimated 200 million clinical cases annually, resulting in more than 580,000 deaths, malaria is not only an important global health problem but also a major factor limiting economic development in developing countries. Interventions that deploy an effective malaria vaccine are regarded as being one of the most cost-effective and reliable means to limit and ultimately eradicate the disease. In recent years, due to increased funding and research, malaria vaccine development has greatly accelerated. The MVW 2016 conference will look at different aspects of vaccine development, assessment and deployment, as well as funding and regulatory aspects of vaccine implementation and testing. The conference will also highlight research on the use of animal models and (controlled) clinical trials to study the immunological basis of protection and to identify novel candidate vaccine antigens.The MVW 2016 meeting will be of interest to scientists, physicians and other professionals from the academic, industrial/commercial and governmental/policy/regulatory sectors that have an interest in vaccine development and global health.

The fourth conference in the series, MALARIA VACCINES FOR THE WORLD – MVW 2016 is the follow-up to the successful MVW meetings held in London, Washington DC and Lausanne and will again offer researchers an international forum to discuss the current status of new malaria vaccines initiatives, vaccine candidates and clinical trials. MVW 2016 will focus attention on Vaccine Issues in relation to Malaria as a worldwide disease.